CA2703224A1 - Pharmaceutical formulation of clavulanic acid - Google Patents

Pharmaceutical formulation of clavulanic acid Download PDF

Info

Publication number
CA2703224A1
CA2703224A1 CA2703224A CA2703224A CA2703224A1 CA 2703224 A1 CA2703224 A1 CA 2703224A1 CA 2703224 A CA2703224 A CA 2703224A CA 2703224 A CA2703224 A CA 2703224A CA 2703224 A1 CA2703224 A1 CA 2703224A1
Authority
CA
Canada
Prior art keywords
clavulanate
pharmaceutical composition
clavulanic acid
tablet
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2703224A
Other languages
English (en)
French (fr)
Inventor
Young Bok Lee
Deog Joong Kim
Chang Ho Ahn
Edward Carl Scholtz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opus Genetics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2703224A1 publication Critical patent/CA2703224A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2703224A 2007-10-26 2008-10-24 Pharmaceutical formulation of clavulanic acid Abandoned CA2703224A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99607907P 2007-10-26 2007-10-26
US60/996,079 2007-10-26
PCT/US2008/012126 WO2009055038A1 (en) 2007-10-26 2008-10-24 Pharmaceutical formulation of clavulanic acid

Publications (1)

Publication Number Publication Date
CA2703224A1 true CA2703224A1 (en) 2009-04-30

Family

ID=40579869

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2703224A Abandoned CA2703224A1 (en) 2007-10-26 2008-10-24 Pharmaceutical formulation of clavulanic acid

Country Status (11)

Country Link
US (1) US20090270358A1 (OSRAM)
EP (1) EP2214680A4 (OSRAM)
JP (1) JP2011500811A (OSRAM)
KR (1) KR20100101574A (OSRAM)
CN (1) CN101918004A (OSRAM)
AU (1) AU2008317315A1 (OSRAM)
BR (1) BRPI0818702A2 (OSRAM)
CA (1) CA2703224A1 (OSRAM)
IL (1) IL205313A0 (OSRAM)
MX (1) MX2010004556A (OSRAM)
WO (1) WO2009055038A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
EP2424498A1 (en) * 2009-04-29 2012-03-07 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
KR101628095B1 (ko) 2010-10-18 2016-06-08 현대자동차 주식회사 저압 ｅｇｒ시스템 제어장치 및 방법
CN102058584B (zh) * 2010-12-30 2012-01-25 石药集团河北中润制药有限公司 克拉维酸钾/微晶纤维素组合物的制备方法
PL3702374T3 (pl) 2012-02-15 2022-11-21 Cydex Pharmaceuticals, Inc. Sposób wytwarzania pochodnych cyklodekstryny
UA121095C2 (uk) 2012-10-22 2020-04-10 Сідекс Фармасьютікалс, Інк. Композиції алкілованого циклодекстрину і способи їх одержання і застосування
PL2919903T3 (pl) 2012-11-14 2020-12-14 W.R. Grace & Co. - Conn. Kompozycje zawierające materiał biologicznie aktywny i nieuporządkowany tlenek nieorganiczny
EP3125873B1 (en) 2014-04-04 2020-06-03 Pharmaquest International Center, LLC Disintegrating monolithic modified release tablets containing quadri-layer extended release granules

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
NZ189022A (en) * 1977-12-08 1981-11-19 Beecham Group Ltd Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9405856D0 (en) * 1994-03-24 1994-05-11 Smithkline Beecham Plc Pharmaceutical formulation
GB9518917D0 (en) * 1995-09-15 1995-11-15 Smithkline Beecham Plc Compounds
IE990159A1 (en) * 1999-02-26 2000-09-20 Fuisz Internat Ltd Storage Stable Amoxycillin and Clavulanate Suspension Composition.
US6627625B1 (en) 1999-08-16 2003-09-30 Revaax Pharmaceuticals, Llc Treatment of behavioral disorders with β-lactam compounds
US6489319B2 (en) 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
WO2002102378A1 (en) 2001-06-18 2002-12-27 Revaax Pharmaceuticals, Llc Therapeutic treatment for sexual dysfunction
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
MX2007001811A (es) * 2004-08-13 2007-03-26 Schering Plough Ltd Formulacion farmaceutica que comprende un antibiotico, un triazol y un corticoesteroide.
DE102006007830A1 (de) * 2006-02-17 2007-08-30 Grünenthal GmbH Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure
MX2008012260A (es) * 2006-03-24 2008-10-07 Panacea Biotec Ltd Composiciones antibioticas de liberacion modificada y procedimiento para su produccion.
EP2424498A1 (en) * 2009-04-29 2012-03-07 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
JP2011500811A (ja) 2011-01-06
BRPI0818702A2 (pt) 2015-04-22
CN101918004A (zh) 2010-12-15
EP2214680A1 (en) 2010-08-11
IL205313A0 (en) 2010-12-30
MX2010004556A (es) 2010-07-01
WO2009055038A1 (en) 2009-04-30
EP2214680A4 (en) 2010-12-29
US20090270358A1 (en) 2009-10-29
AU2008317315A1 (en) 2009-04-30
KR20100101574A (ko) 2010-09-17

Similar Documents

Publication Publication Date Title
EP2566462B1 (en) Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US10441585B2 (en) Formulations containing nalbuphine and uses thereof
US4673564A (en) Sustained release pharmaceutical composition of solid medical material
US20100255099A1 (en) Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
US20090270358A1 (en) Pharmaceutical formulation of clavulanic acid
EP2413913B1 (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
JP2021525739A (ja) グルコキナーゼ活性化剤およびｋ−ａｔｐチャネル遮断薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用
US20100112056A1 (en) Immediate release dosage forms of sodium oxybate
US11020351B2 (en) Stable bilayer tablet compositions
WO2021123165A1 (en) Dosage form comprising amorphous solid solution of empagliflozin with polymer
WO2011093832A2 (en) Stable efervescent formulations comprising cefaclor
CZ280847B6 (cs) Peroorálně aplikovatelná forma léku pro léčení centrálních stavů nedostatku dopaminu
WO2020109319A1 (en) Pharmaceutical composition comprising ramipril and indapamide
WO2009084036A2 (en) Composition for treatment of viral infections
RU2240784C1 (ru) Лекарственное средство на основе арбидола
WO2022119541A1 (en) A film coated tablet formulation comprising dapagliflozin and metformin hydrochloride
US20050181055A1 (en) Pharmaceutical compositions of quinapril
KR20110104903A (ko) 안정성이 개선된 프라미펙솔을 함유하는 약제학적 조성물 및 이의 제조방법
EP4637725A1 (en) Stable pharmaceutical composition containing dapagliflozin and sitagliptin and process for the preparation thereof
WO2022153334A1 (en) Transmucosal dosage forms of foscarnet
HK1182964A (en) Immediate release formulations and dosage forms of gamma-hydroxybutyrate
HK1182964B (en) Immediate release formulations and dosage forms of gamma-hydroxybutyrate

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20141024